tiprankstipranks
Avalo Therapeutics, Inc. (AVTX)
NASDAQ:AVTX
US Market
Want to see AVTX full AI Analyst Report?

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

1,095 Followers
See the Price Targets and Ratings of:

AVTX Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Avalo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVTX Stock 12 Month Forecast

Average Price Target

$44.90
▲(143.49% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $44.90 with a high forecast of $60.00 and a low forecast of $34.00. The average price target represents a 143.49% change from the last price of $18.44.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","32":"$32","61":"$61","17.5":"$17.5","46.5":"$46.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,17.5,32,46.5,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.29,20.575384615384614,23.86076923076923,27.146153846153844,30.43153846153846,33.71692307692308,37.002307692307696,40.28769230769231,43.573076923076925,46.85846153846154,50.143846153846155,53.42923076923077,56.714615384615385,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.29,19.41384615384615,21.537692307692307,23.661538461538463,25.785384615384615,27.909230769230767,30.033076923076923,32.15692307692308,34.28076923076923,36.40461538461538,38.52846153846154,40.652307692307694,42.776153846153846,{"y":44.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.29,18.575384615384614,19.86076923076923,21.146153846153844,22.43153846153846,23.716923076923074,25.002307692307692,26.287692307692307,27.573076923076922,28.858461538461537,30.14384615384615,31.42923076923077,32.714615384615385,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$44.90Lowest Price Target$34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on AVTX
Leerink Partners
Leerink Partners
$38
Buy
106.07%
Upside
Initiated
07/06/26
Avalo Therapeutics initiated with an Outperform at LeerinkAvalo Therapeutics initiated with an Outperform at Leerink
Bank of America Securities Analyst forecast on AVTX
Bank of America Securities
Bank of America Securities
$35
Buy
89.80%
Upside
Initiated
06/12/26
Avalo Therapeutics initiated with a Buy at BofAAvalo Therapeutics initiated with a Buy at BofA
TD Cowen Analyst forecast on AVTX
TD Cowen
TD Cowen
Buy
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on AVTX
Stifel Nicolaus
Stifel Nicolaus
$36$39
Buy
111.50%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Immunic (NASDAQ: IMUX)
Citizens JMP Analyst forecast on AVTX
Citizens JMP
Citizens JMP
$62$55
Buy
198.26%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $55 from $62 at CitizensAvalo Therapeutics price target lowered to $55 from $62 at Citizens
Mizuho Securities Analyst forecast on AVTX
Mizuho Securities
Mizuho Securities
$39$45
Buy
144.03%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target raised to $45 from $39 at MizuhoAvalo Therapeutics price target raised to $45 from $39 at Mizuho
H.C. Wainwright Analyst forecast on AVTX
H.C. Wainwright
H.C. Wainwright
$40$35
Buy
89.80%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $35 from $40 at H.C. WainwrightAvalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
Wedbush
$40$34
Buy
84.38%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $34 from $40 at WedbushAvalo Therapeutics price target lowered to $34 from $40 at Wedbush
BTIG
$58
Buy
214.53%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), NeuroPace (NASDAQ: NPCE) and Avalo Therapeutics (NASDAQ: AVTX)
Piper Sandler Analyst forecast on AVTX
Piper Sandler
Piper Sandler
$48$60
Buy
225.38%
Upside
Assigned
05/11/26
Avalo Therapeutics price target raised to $60 from $48 at Piper SandlerAvalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Guggenheim Analyst forecast on AVTX
Guggenheim
Guggenheim
$50
Buy
171.15%
Upside
Reiterated
05/06/26
Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Wolfe Research Analyst forecast on AVTX
Wolfe Research
Wolfe Research
$48
Buy
160.30%
Upside
Initiated
04/08/26
Avalo Therapeutics initiated with an Outperform at Wolfe ResearchAvalo Therapeutics initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on AVTX
Oppenheimer
Oppenheimer
$35
Buy
89.80%
Upside
Reiterated
09/29/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Cantor Fitzgerald Analyst forecast on AVTX
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Berenberg Bank Analyst forecast on AVTX
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$52.4$19.36
Buy
5.02%
Upside
Initiated
08/06/25
Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on AVTX
Leerink Partners
Leerink Partners
$38
Buy
106.07%
Upside
Initiated
07/06/26
Avalo Therapeutics initiated with an Outperform at LeerinkAvalo Therapeutics initiated with an Outperform at Leerink
Bank of America Securities Analyst forecast on AVTX
Bank of America Securities
Bank of America Securities
$35
Buy
89.80%
Upside
Initiated
06/12/26
Avalo Therapeutics initiated with a Buy at BofAAvalo Therapeutics initiated with a Buy at BofA
TD Cowen Analyst forecast on AVTX
TD Cowen
TD Cowen
Buy
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on AVTX
Stifel Nicolaus
Stifel Nicolaus
$36$39
Buy
111.50%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Immunic (NASDAQ: IMUX)
Citizens JMP Analyst forecast on AVTX
Citizens JMP
Citizens JMP
$62$55
Buy
198.26%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $55 from $62 at CitizensAvalo Therapeutics price target lowered to $55 from $62 at Citizens
Mizuho Securities Analyst forecast on AVTX
Mizuho Securities
Mizuho Securities
$39$45
Buy
144.03%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target raised to $45 from $39 at MizuhoAvalo Therapeutics price target raised to $45 from $39 at Mizuho
H.C. Wainwright Analyst forecast on AVTX
H.C. Wainwright
H.C. Wainwright
$40$35
Buy
89.80%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $35 from $40 at H.C. WainwrightAvalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
Wedbush
$40$34
Buy
84.38%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $34 from $40 at WedbushAvalo Therapeutics price target lowered to $34 from $40 at Wedbush
BTIG
$58
Buy
214.53%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), NeuroPace (NASDAQ: NPCE) and Avalo Therapeutics (NASDAQ: AVTX)
Piper Sandler Analyst forecast on AVTX
Piper Sandler
Piper Sandler
$48$60
Buy
225.38%
Upside
Assigned
05/11/26
Avalo Therapeutics price target raised to $60 from $48 at Piper SandlerAvalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Guggenheim Analyst forecast on AVTX
Guggenheim
Guggenheim
$50
Buy
171.15%
Upside
Reiterated
05/06/26
Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Wolfe Research Analyst forecast on AVTX
Wolfe Research
Wolfe Research
$48
Buy
160.30%
Upside
Initiated
04/08/26
Avalo Therapeutics initiated with an Outperform at Wolfe ResearchAvalo Therapeutics initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on AVTX
Oppenheimer
Oppenheimer
$35
Buy
89.80%
Upside
Reiterated
09/29/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Cantor Fitzgerald Analyst forecast on AVTX
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Berenberg Bank Analyst forecast on AVTX
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$52.4$19.36
Buy
5.02%
Upside
Initiated
08/06/25
Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
5/7 ratings generated profit
71%
Average Return
+33.67%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +33.67% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
7/7 ratings generated profit
100%
Average Return
+68.46%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +68.46% per trade.
2 Years
Mitchell KapoorH.C. Wainwright
Success Rate
7/7 ratings generated profit
100%
Average Return
+86.71%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVTX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
11
12
21
15
13
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
12
21
16
14
In the current month, AVTX has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the past 3 months is 44.90.
Each month's total comprises the sum of three months' worth of ratings.

AVTX Financial Forecast

AVTX Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

AVTX Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

AVTX Stock Forecast FAQ

What is AVTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics, Inc.’s 12-month average price target is 44.90.
    What is AVTX’s upside potential, based on the analysts’ average price target?
    Avalo Therapeutics, Inc. has 143.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVTX a Buy, Sell or Hold?
          Avalo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avalo Therapeutics, Inc.’s price target?
            The average price target for Avalo Therapeutics, Inc. is 44.90. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $34.00. The average price target represents 143.49% Increase from the current price of $18.44.
              What do analysts say about Avalo Therapeutics, Inc.?
              Avalo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of AVTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.